Introduction
============

Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), also known as CD66a is a key molecule in several intracellular and intercellular signaling pathways, with multiple functional and structural roles. It is expressed in some normal cells (epithelial cells of large bowel, prostate, bile duct, salivary ducts, endothelial cells, T lymphocytes) and also in several tumors (melanoma, non-small cell lung carcinomas, breast, large bowel, gastric, thyroid carcinoma) ([@b1-ol-0-0-10067]). CEACAM1 is a transmembrane protein that includes an extracellular N-terminal variable domain and three constant C2-like immunoglobulin domains ([@b2-ol-0-0-10067]). Its extracellular domain is responsible for homophilic (CEACAM1-CEACAM1) and heterophilic intercellular adhesion with CEA and T cell immunoglobulin and mucin domain ([@b3-ol-0-0-10067]).

CEACAM1 expression in melanoma was studied as diagnosis marker, as well as a prognosis and treatment efficacy indicator ([@b4-ol-0-0-10067],[@b5-ol-0-0-10067]). CEACAM1 expression has often been described in the invading part of the tumor and associated with increased melanoma cell invasion and migration and a poor prognosis ([@b4-ol-0-0-10067],[@b6-ol-0-0-10067]--[@b8-ol-0-0-10067]). Although initially it was identified as a tumor suppressor, with roles in apoptosis and tumorigenesis ([@b9-ol-0-0-10067]), CEACAM1 demonstrates involvement in a mechanism used by tumor cells to evade the immune system, especially cytotoxic lymphocyte attack ([@b4-ol-0-0-10067]). In melanoma, through homophilic interactions, CEACAM1 inhibits natural killer (NK) cell activity, as well as immune functions of tumor infiltrating lymphocytes (TILs), such as cytotoxicity and IFN-γ release ([@b3-ol-0-0-10067],[@b4-ol-0-0-10067],[@b6-ol-0-0-10067],[@b10-ol-0-0-10067],[@b11-ol-0-0-10067]). Some patients with melanoma have increased serum levels of CEACAM1, described as a factor of poor prognosis, predicting response failure to immunotherapy and tendency to early progression and metastasis ([@b6-ol-0-0-10067],[@b12-ol-0-0-10067],[@b13-ol-0-0-10067]). These serum levels can also be used in patient surveillance as indicators for tumor progression and treatment response ([@b6-ol-0-0-10067],[@b12-ol-0-0-10067],[@b13-ol-0-0-10067]).

For the above reasons, CEACAM1 was identified as potential therapeutic target in melanoma, and some monoclonal antibodies against CEACAM1 were designed and studied in melanoma immunotherapy ([@b14-ol-0-0-10067]).

Some studies compared CEACAM1 expression in various melanocytic lesions and identified an increased expression correlated with the severity and evolutive potential of the lesion: CEACAM1 was negative in non-tumoral melanocytes, positive in very few common nevi and increasingly more frequenty positive in dysplastic nevi, thin melanomas, thick melanomas and melanoma metastasis ([@b10-ol-0-0-10067],[@b15-ol-0-0-10067],[@b16-ol-0-0-10067]).

There are still only a few studies concerning special characteristics of CEACAM1 expression in melanoma and their correlations with other morphologic and immunohistochemical traits of tumors. Especially, in thin melanomas the data can help in stratifying patients according their risk to progression and poor outcome, since there is a significant variability of these patients evolution ([@b17-ol-0-0-10067]).

On the other hand, regression in melanoma is a studied feature, with controversial biologic potential. It is defined as decrease of the number of tumor cells accompanied by stromal reaction (fibrosis, inflammatory infiltrate with variable number of melanophages, capillaries ectasias), determined by the immune response of the host ([@b18-ol-0-0-10067],[@b19-ol-0-0-10067]). Some studies credited regression with an aggressive comportment, and, although it is not included in staging, there are opinions supporting the idea that presence of histological confirmed regression is an indicator for sentinel node biopsy in patients with thin melanomas ([@b17-ol-0-0-10067],[@b18-ol-0-0-10067]). Multiple efforts were made to identify the best way to characterize regression in order to make it a reproducible routine feature to be reported by pathologists ([@b20-ol-0-0-10067]). Three types of regression (complete, segmentary and partial) have been described with different incidence and different impact on patient outcome ([@b20-ol-0-0-10067]). Globally, regression is present in about half of melanomas, being less frequent in thick melanomas ([@b20-ol-0-0-10067]).

Similar lesions occur in benign melanocytic tumors ('halo nevi') but there are evident morphologic differences with areas of regression in melanoma beyond the atypical character of the melanoma cells: distribution of the tumor cells and lymphocytes and the lack of fibrosis in benign lesions ([@b21-ol-0-0-10067]).

Mechanisms of regression in melanoma are multifactorial and still controversial. It is an inflammatory immune-mediated pathway involving CD8-positive cytotoxic T lymphocytes and NK cells ([@b18-ol-0-0-10067]). Probably the trigger of regression is a melanocytic antigen ([@b22-ol-0-0-10067]), destruction of tumor cells being mediated by an inflammatory response of the host ([@b18-ol-0-0-10067]).

We studied CEACAM1 expression in regressing versus non-regressing thin melanomas, knowing that the phenomenon of regression represents a valuable model for understanding tumor immunity ([@b23-ol-0-0-10067]).

Materials and methods
=====================

The retrospective study included 53 consecutive cases of thin melanoma, 21 with regression and 32 without. We used the cut-off value for thin melanoma of 2 mm, corresponding to stage 1 and 2 tumors. All the cases were diagnosed in Colentina University Hospital, Department of Pathology in last two years, using histopathological and immunohistochemical techniques. Clinical and histological data were collected and all cases were reexamined by two independent senior pathologists, using Nikon Eclipse E200 microscope (Nikon Instruments Europe B.V., Amsterdam, The Netherlands). Multiple features were analyzed: tumor subtype, thickness, presence or absence of ulceration, mitotic index, Breslow and Clark levels, CEACAM expression.

This study was performed on patients who previously signed a written informed consent and it was approved by the Ethics Committee of Colentina University Hospital. Slides used for research purposes were sectioned after the final diagnosis was signed and did not exhaust the biological material in paraffin blocks, allowing further tests if needed.

All specimens were collected from skin surgical resections of tumors. After surgical resection, samples were immediately immersed in 10% buffered formalin, then automatically processed using a Leica ASP300 S Fully Enclosed Tissue Processor (Leica Biosystems, Newcastle, UK) and embedded in paraffin. Multiple 3-µm sections were obtained for usual and special stains. After examining hematoxylin and eosin slides, all cases were subjected to appropriate immunohistochemical stains for diagnostic confirmation. In all cases, the final diagnosis was malignant melanoma with Breslow index \<2 mm.

For this study, serial sections from the formalin-fixed, paraffin-embedded blocks were obtained and used for detection of CEACAM1 using three different isoforms of the marker (AA 1-428, extracellular domain, rabbit, cat. no. ABIN1997563; AA 1-428, mouse, clone 8B6E2F4 cat. no. ABIN 1997555; and AA 1-468, full length, mouse, clone 2F6, cat. no. ABIN513717; all from antibodies-online GmbH, Aachen, Germany). Tissue thin sections (3 µm) were deparaffinized in xylene, rehydrated with increasing dilutions of ethanol and then with water, and pretreated in a steamer for 30 min in citrate buffer (10 mM, pH 6.0). Slides were washed in Tris-buffered saline (TBS, pH 7.4) and endogenous peroxidase activity was blocked by treatment with peroxidase block, then, incubated with CEACAM1 isoforms ([Table I](#tI-ol-0-0-10067){ref-type="table"}).

Then, slides were examined and membrane positivity for CEACAM-1 was assessed in tumor cells. There were comparatively analyzed tumor cells from areas of partial regression and areas without regression in regressed melanomas and the most intensely positive areas in non-regressed melanoma. Also, we assessed the intensity of the expression in different areas of the tumors (junctional, dermal, invasion front), and classified it on a semi-quantitative scale: 0, absent; 1, weak positivity; 2, moderate positivity; and 3, intense positivity.

The data were introduced into a data base and statistically analyzed using Microsoft Excel and SPSS (IBM Corp., Released 2015, IBM SPSS Statistics for Windows, version 23.0, Armonk, NY, USA). Welch\'s t-test and Pearson correlation test were used. P-value \<0.05 was considered to indicate a statistically significant difference.

Results
=======

Of our samples, 52 cases were superficial spreading melanomas and just one case (with regression) was an acral-lentiginous melanoma. Also, just one case (regressed) had ulceration, all the others lacked this feature.

Median Breslow index of tumors included in the study was 0.688 mm (with values between 0.16 and 1.75 mm), higher in non-regressed melanomas (0.770 mm) than in regressed ones (0.660 mm).

Mitotic index was evaluated by quantifying the number of mitotic figures on one square millimeter, in hot spots, the values ranged between 0 and 9 mitotic figures, with an average value of 1 for the entire group ([Fig. 1](#f1-ol-0-0-10067){ref-type="fig"}).

All three isoforms of CEACAM-1 had similar reactivity. CEACAM-1 was positive in epithelial cells of sweat ducts and sebaceous glands (used as positive internal control) ([Fig. 2](#f2-ol-0-0-10067){ref-type="fig"}).

From the 32 cases of melanoma without regression, only in 3 cases CEACAM-1 was negative in tumor cells, in all the other cases membrane positivity was identified: weak (13 cases), mild (14 cases) and strong (2 cases) ([Fig. 3](#f3-ol-0-0-10067){ref-type="fig"}).

In the group of regressed melanomas, a significant difference was observed between remaining (non-regressed) tumor cells from regressed areas ([Fig. 4](#f4-ol-0-0-10067){ref-type="fig"}) and tumor cells from non-regressed areas ([Fig. 5](#f5-ol-0-0-10067){ref-type="fig"}). While in regressed areas, tumor cells were negative for CEACAM-1 in 16 cases and weakly positive in only 5 cases, in the same group, in non-regressed areas, tumor cells were positive in 19 cases and negative in only 2 cases ([Fig. 5](#f5-ol-0-0-10067){ref-type="fig"}).

Statistical correlations showed that the difference of CEACAM-1 reactivity in tumor cells from regressed and non-regressed area ([Fig. 6](#f6-ol-0-0-10067){ref-type="fig"}) is highly significant (t-test, P\<0.0001) ([Fig. 7](#f7-ol-0-0-10067){ref-type="fig"}).

Correlation between Breslow index and CEACAM-1 reactivity was significant only in regressed melanomas (Pearson correlation test, P=0.22589). Practically, thicker tumors had stronger global positivity for CEACAM-1 in all studied tumors, but the correlation was not statistically significant in non-regressed melanomas.

In 34 cases, representing approximately 64%, we observed a stronger expression of CEACAM-1 in tumor cells from the deep invasion front ([Fig. 8](#f8-ol-0-0-10067){ref-type="fig"}). This feature was observed both in regressed melanomas (11 out of 21) and non-regressed tumors (23 out of 32) ([Fig. 9](#f9-ol-0-0-10067){ref-type="fig"}).

Discussion
==========

Superficial spreading melanoma is the most frequent subtype and a less aggressive form of the tumor. Since it has a long period of radial growth, without invasion, it is the most probable tumor to be diagnosed as thin melanoma ([@b24-ol-0-0-10067]). In our study, the vast majority of thin melanomas were superficial spreading type, with nodular growth and invasion. Ulceration is also a rare feature in thin melanomas but is considered a poor prognosis factor related with positive sentinel node and significant risk of metastasis ([@b25-ol-0-0-10067]--[@b27-ol-0-0-10067]). In our group only one tumor was ulcerated, a regressed superficial spreading melanoma with high mitotic index ([@b9-ol-0-0-10067]) and Breslow level 1.4 mm, confirming the aggressive potential of this proliferation. In this particular tumor, CEACAM-1 was weakly positive in regressed areas and strongly positive in non-regressed areas. Considering that CEACAM-1 is a membrane protein that promotes invasion and metastasis in melanoma, this characteristic confirms the fact that this tumor could have a poor outcome ([@b28-ol-0-0-10067]). Immunohistochemical testing for CEACAM-1 in melanomas could help stratifying patients according to their risk to progression and represents an interesting feature that can represent not only a therapeutical target, but also a morphologic trait that helps personalizing the treatment and surveillance in melanoma patients.

CEACAM-1 is positive in the vast majority of cases of melanoma, but our study identified a significant difference between the intensity of reaction in various areas of the tumor. Melanomas without regression and areas without regression from regressed melanomas showed a similar profile of CEACAM-1 positivity, while melanomas with regression exhibited a very low rate of CEACAM-1 positivity in remaining tumor cells form regressed areas. This specific immunophenotype implies that these tumor cells have special characteristics and lack a feature that confers their counterparts from non-regressed areas with potential of invasion. This observation raises two hypotheses: either regression affects only some tumor cells, less aggressive, with special features, or inflammatory cells and inflammatory mediators are inducing changes in tumor cell phenotype and behaviour.

Some studies demonstrated that CEACAM-1 enhances vascular neo-proliferation and reduces cell sensitivity to hypoxia, mechanism involved in inflammatory-driven tumor regression ([@b29-ol-0-0-10067],[@b30-ol-0-0-10067]). These data suggest that CEACAM-1 defective cells are more sensitive to hypoxia and less capable of stimulating tumor angiogenesis. Also, CEACAM-1 expression modulates apoptosis ([@b10-ol-0-0-10067]). These characteristics make tumor cells more sensitive to microenvironment changes induced by inflammation and more prone to be destroyed by T lymph cells and NK cells. Melanoma is a poor immunogenic tumor in advanced stages leading to immune suppression and consequently to immune tolerance by so-called 'immunosculpting' process ([@b31-ol-0-0-10067],[@b32-ol-0-0-10067]).

On the other hand, our study confirms that CEACAM-1 is overexpressed in cells from the invasion front, in regressed and non-regressed melanomas. This is related in all studies with a decrease of cell-adhesion and a higher capacity of stromal invasion ([@b28-ol-0-0-10067],[@b33-ol-0-0-10067]). Overexpression of CEACAM-1 in front invasion cells represents an important dysregulation of cell adhesion, enhancing the transition from radial growth phase (with good prognosis and reduced risk of metastasis) to vertical growth phase (with high risk of metastasis and poor prognosis) ([@b33-ol-0-0-10067],[@b34-ol-0-0-10067]). CEACAM-1 may intervene in mechanisms involved in immune surveillance escaping ([@b35-ol-0-0-10067],[@b36-ol-0-0-10067]) and it is a possible candidate to be a monitoring biomarker and a possible target; supplementary investigations are necessary ([@b3-ol-0-0-10067],[@b37-ol-0-0-10067],[@b38-ol-0-0-10067]).

CEACAM1 is a valuable marker in melanoma that can be used for a more complete description of tumor features related to invasiveness and aggressive behavior. It is more intensely positive in thick melanomas and in invasion front, indicating that CEACAM1-positive cells have a higher potential of invasion and metastasis.

Also, there is significant loss of CEACAM1 expression in melanoma cells from areas of regression indicating that regression is not only the result of inflammation, but also of some specific characteristics of some tumor cells that make them more sensitive to the cytotoxic lymphocyte action.

Monoclonal antibodies against CEACAM1 can induce loss of CEACAM1 expression in melanoma cells and enhance antitumor effect of patients\' immune system and has been evaluated in a phase 1 study for safety and tolerability (NCT02346955) completed in 2017 (<https://clinicaltrials.gov/ct2/show/NCT02346955>; identification no. NCT02346955). Phase 2 clinical trials will further evaluate the adequate doses. CEACAM1 is a promising therapeutic target, since loss of expression in tumor cells seems to stimulate regression and inhibit vertical growth and invasion.
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![Most thin melanomas have a low mitotic rate.](ol-17-05-4149-g00){#f1-ol-0-0-10067}

![Intense membrane positivity for CEACAM-1 in a melanoma case. CEACAM1. AA 1-428, rabbit; magnification ×100.](ol-17-05-4149-g01){#f2-ol-0-0-10067}

![Melanomas without regression are mostly positive for CEACAM-1, with variable intensity of the stain.](ol-17-05-4149-g02){#f3-ol-0-0-10067}

![Tumor cells in regressed areas are mostly negative for CEACAM-1.](ol-17-05-4149-g03){#f4-ol-0-0-10067}

![In non-regressed areas of melanomas with regression, tumor cells are mostly positive for CEACAM-1.](ol-17-05-4149-g04){#f5-ol-0-0-10067}

![Melanoma with regression. Note mild positivity (arrow) for CEACAM-1 in junctional component and loss of positivity (circle) in the few tumor cells from the regression area. CEACAM1. AA 1--428, mouse; magnification ×100.](ol-17-05-4149-g05){#f6-ol-0-0-10067}

![Differences between CEACAM-1 positivity in tumor cells from regressed and non-regressed areas of melanomas with regression.](ol-17-05-4149-g06){#f7-ol-0-0-10067}

![Significant enhancement of CEACAM-1 positivity in the invasion front of a melanoma without regression. Note that the intensity of the staining is higher in the lower half of the image (profound area). CEACAM1. AA 1--428, mouse; magnification ×100.](ol-17-05-4149-g07){#f8-ol-0-0-10067}

![Similar pattern of enhancement of CEACAM-1 expression in melanomas with and without regression.](ol-17-05-4149-g08){#f9-ol-0-0-10067}

###### 

Markers used in this study.

  Epitope     Host     Clonality      Specificity          Supplier
  ----------- -------- -------------- -------------------- ------------------------
  AA 1--428   Rabbit   Polyclonal     Human CEACAM1/CD66   antibodies-online GmbH
  AA 1--428   Mouse      Monoclonal   Human CEACAM1/CD66   antibodies-online GmbH
  AA 1--468   Mouse      Monoclonal   Human CEACAM1/CD66   antibodies-online GmbH
